Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens.

[1]  S. Tompkins,et al.  A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. , 1993, Journal of immunological methods.

[2]  Charles A. Janeway,et al.  Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs , 1992, Nature.

[3]  V Brusic,et al.  Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. , 1998, Journal of immunology.

[4]  P. Cresswell,et al.  Presentation of viral antigen controlled by a gene in the major histocompatibility complex , 1990, Nature.

[5]  J. Schmitz,et al.  Cytotoxic T lymphocytes specific for the simian immunodeficiency virus , 1999, Immunological reviews.

[6]  V. Brusic,et al.  Neural network-based prediction of candidate T-cell epitopes , 1998, Nature Biotechnology.

[7]  O Ouchterlony,et al.  Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. , 1988, Journal of immunological methods.

[8]  E. Padlan,et al.  H-2Dd exploits a four residue peptide binding motif , 1993, The Journal of experimental medicine.

[9]  R. Karr,et al.  Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association , 1995, The Journal of experimental medicine.

[10]  P. Jensen,et al.  Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH , 1991, The Journal of experimental medicine.

[11]  L. Borysiewicz,et al.  The use of human leucocyte antigen class I transgenic mice to investigate human immune function. , 1998, Journal of immunological methods.

[12]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[13]  John Sidney,et al.  HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles1 2 , 2000, The Journal of Immunology.

[14]  P. Schlenke,et al.  Expression and kinetics of cytokines determined by intracellular staining using flow cytometry. , 1999, Journal of immunological methods.

[15]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[16]  C. Figdor,et al.  The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. , 1999, Cancer research.

[17]  O. Schueler‐Furman,et al.  Structure‐based prediction of binding peptides to MHC class I molecules: Application to a broad range of MHC alleles , 2000, Protein science : a publication of the Protein Society.

[18]  E. Celis,et al.  Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. , 2000, Cancer research.

[19]  P. Kloetzel,et al.  A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. , 1999, Journal of molecular biology.

[20]  R. Orlando,et al.  A new liquid chromatography/tandem mass spectrometric approach for the identification of class I major histocompatibility complex associated peptides that eliminates the need for bioassays. , 1999, Rapid communications in mass spectrometry : RCM.

[21]  C DeLisi,et al.  T-cell antigenic sites tend to be amphipathic structures. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Cécile Gouttefangeas,et al.  Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.

[23]  A Sette,et al.  Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.

[24]  H. Rammensee,et al.  Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome‐dependent and ‐independent proteolytic activities , 1998, European journal of immunology.

[25]  B. Chapuis,et al.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. , 1968, Immunology.

[26]  C. Cheng‐Mayer,et al.  Human Immunodeficiency Virus Type 1 Envelope Epitope-Specific CD4+ T Lymphocytes in Simian/Human Immunodeficiency Virus-Infected and Vaccinated Rhesus Monkeys Detected Using a Peptide-Major Histocompatibility Complex Class II Tetramer , 2000, Journal of Virology.

[27]  Günter J. Hämmerling,et al.  Selectivity of MHC-encoded peptide transporters from human, mouse and rat , 1994, Nature.

[28]  D. Schadendorf,et al.  Identification of a new HLA‐A*0201‐restricted T‐cell epitope from the tyrosinase‐related protein 2 (TRP2) melanoma antigen , 2000, International journal of cancer.

[29]  W. Taylor,et al.  A sequence pattern common to T cell epitopes. , 1988, The EMBO journal.

[30]  V. Brusic,et al.  Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells , 2000 .

[31]  Taku Suto,et al.  An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries , 2000, Immunogenetics.

[32]  D. Jewell,et al.  Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection. , 1998, Journal of immunology.

[33]  O Ouchterlony,et al.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[34]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[35]  Ferry Ossendorp,et al.  Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis , 2001, The Journal of experimental medicine.

[36]  J. Drijfhout,et al.  A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. , 1995, Human immunology.

[37]  A. Goldberg,et al.  Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[39]  P. Marrack,et al.  Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Szekely,et al.  Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay , 1994, European journal of immunology.

[41]  Vladimir Brusic,et al.  Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network , 1998, Bioinform..

[42]  T. Logtenberg,et al.  Enumeration of IFN-γ-producing human lymphocytes by spot-ELISA: A method to detect lymphokine-producing lymphocytes at the single-cell level , 1988 .

[43]  H. Rammensee,et al.  Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products , 2001, The Journal of experimental medicine.

[44]  R. Walsky,et al.  High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  H. Ljunggren,et al.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.

[46]  J. Sidney,et al.  Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. , 1991, Journal of immunology.

[47]  P. Doherty,et al.  Accessing complexity: the dynamics of virus-specific T cell responses. , 2000, Annual review of immunology.

[48]  V Brusic,et al.  NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.

[49]  K. Hadeler,et al.  PAProC: a prediction algorithm for proteasomal cleavages available on the WWW , 2001, Immunogenetics.

[50]  R. R. Mallios,et al.  Class II MHC quantitative binding motifs derived from a large molecular database with a versatile iterative stepwise discriminant analysis meta- algorithm , 1999, Bioinform..

[51]  H. Rammensee,et al.  Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. , 1994, Journal of immunology.

[52]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[53]  Scott W. Reid,et al.  HLA Class I Binding Motifs Derived from Random Peptide Libraries Differ at the COOH Terminus from Those of Eluted Peptides , 1997, The Journal of experimental medicine.

[54]  A Sette,et al.  A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets. , 1997, Human immunology.

[55]  Søren Buus,et al.  Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding , 1996, European journal of immunology.

[56]  K. Parker,et al.  Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Lotze,et al.  Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[58]  B. Sander,et al.  Detection of Individual Interleukin 4‐ and Gamma Interferon‐Producing Murine Spleen Cells after Activation with T‐Cell Mitogens , 1989, Scandinavian journal of immunology.

[59]  B. Sander,et al.  Assessment of Cytokines by Immunofluorescence and the Paraformaldehyde‐Saponin Procedure , 1991, Immunological reviews.

[60]  A Sette,et al.  Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.

[61]  J. Salamero,et al.  Homozygous human TAP peptide transporter mutation in HLA class I deficiency. , 1994, Science.

[62]  Peter Walden,et al.  Exact prediction of a natural T cell epitope , 1991, European journal of immunology.

[63]  H. Grey,et al.  Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[64]  C. Heusser,et al.  Detection of intracellular cytokines by flow cytometry. , 1993, Journal of immunological methods.

[65]  G. Pawelec,et al.  Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. , 1997, Cancer research.

[66]  Z. Nagy,et al.  Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.

[67]  Andrew W. Liu,et al.  HLA-DQ Tetramers Identify Epitope-Specific T Cells in Peripheral Blood of Herpes Simplex Virus Type 2-Infected Individuals: Direct Detection of Immunodominant Antigen-Responsive Cells1 , 2000, The Journal of Immunology.

[68]  H. Rammensee,et al.  The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. , 1996, Cancer research.

[69]  Andrew W. Liu,et al.  Distinct T Cell Interactions with HLA Class II Tetramers Characterize a Spectrum of TCR Affinities in the Human Antigen-Specific T Cell Response1 , 2000, The Journal of Immunology.

[70]  P. Romero,et al.  Production of IL 2 and IFN-gamma by T cells from malaria patients in response to Plasmodium falciparum or erythrocyte antigens in vitro. , 1985, Journal of immunology.

[71]  Kendall A. Smith,et al.  T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.

[72]  R. Robb,et al.  An ELISA-based assay for quantitation of human interleukin 2. , 1984, Journal of immunological methods.

[73]  D. Zaller,et al.  Prediction of peptide affinity to HLA DRB1*0401. , 1994, International archives of allergy and immunology.

[74]  A Sette,et al.  Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.

[75]  J. Sidney,et al.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.

[76]  H. Rammensee,et al.  Cell lines transfected with the TAP inhibitor ICP47 allow testing peptide binding to a variety of HLA class I molecules. , 1998, International immunology.

[77]  H. Kalbacher,et al.  New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. , 1996, European journal of biochemistry.

[78]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[79]  Andrew W. Liu,et al.  MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. , 1999, The Journal of clinical investigation.

[80]  Matteo Bellone,et al.  Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.

[81]  W Keilholz,et al.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Steven A. Rosenberg,et al.  Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice , 2000, The Journal of Immunology.

[83]  A. Steere,et al.  Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[84]  H. Rammensee,et al.  The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis , 1999, Immunogenetics.

[85]  F. Marincola,et al.  Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. , 2000, Journal of the National Cancer Institute.

[86]  C. Scheibenbogen,et al.  Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. , 1997, Journal of immunological methods.

[87]  K. Livak,et al.  Real time quantitative PCR. , 1996, Genome research.

[88]  H. Rammensee,et al.  A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  Klas Kärre,et al.  Assessment of major histocompatibility complex class I interaction with Epstein‐Barr virus and human immunodeficiency virus peptides by elevation of membrane H‐2 and HLA in peptide loading‐deficient cells , 1992, European journal of immunology.

[90]  M. Esteban,et al.  Quantification of antigen specific CD8+ T cells using an ELISPOT assay. , 1995, Journal of immunological methods.

[91]  Andreas Radbruch,et al.  Enrichment and detection of live antigen‐specific CD4+ and CD8+ T cells based on cytokine secretion , 1999, European journal of immunology.

[92]  S. H. van der Burg,et al.  An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. , 1995, Human immunology.

[93]  Søren Buus,et al.  A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules , 1994, European journal of immunology.

[94]  A. D. De Groot,et al.  An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. , 1997, AIDS research and human retroviruses.

[95]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[96]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[97]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[98]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[99]  B. Gückel,et al.  A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. , 2001, Cancer research.

[100]  P. Marrack,et al.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.

[101]  A. Lohse,et al.  Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. , 1996, Journal of immunological methods.

[102]  P. Rieckmann,et al.  Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. , 1997, Journal of immunological methods.

[103]  H. Rammensee,et al.  A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. , 1996, Journal of immunological methods.

[104]  E. Pamer,et al.  Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes , 1991, Nature.

[105]  H. Schellekens,et al.  Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. , 1985, Journal of immunological methods.

[106]  S. Buus,et al.  Biochemical analysis of peptide binding to MHC class I , 1996 .

[107]  Y. Cui,et al.  Computer-assisted, quantitative cytokine enzyme-linked immunospot analysis of human immune effector cell function. , 1997, BioTechniques.

[108]  J. Cerottini,et al.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. , 1974, Advances in immunology.

[109]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[110]  R. Zinkernagel,et al.  Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes , 1998, The Journal of experimental medicine.

[111]  J A Koziol,et al.  Prediction of binding to MHC class I molecules. , 1995, Journal of immunological methods.

[112]  P. Openshaw,et al.  Flow cytometric measurement of intracellular cytokines. , 2000, Journal of immunological methods.

[113]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[114]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[115]  S Miltenyi,et al.  Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[116]  A Sette,et al.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.

[117]  J. Skolnick,et al.  Application of an artificial neural network to predict specific class I MHC binding peptide sequences , 1998, Nature Biotechnology.

[118]  L. Fugger,et al.  HLA class II transgenic mice: models of the human CD4+ T‐cell immune response , 1999, Immunological reviews.

[119]  M. Lotze,et al.  Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. , 1994, Human immunology.